P173 | CLINICAL EFFICACY OF ISATUXIMAB PLUS CARFILZOMIB AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: 2025 DATA UPDATE

Introduction Isatuximab, a novel anti-CD38 monoclonal antibody, has demonstrated significant efficacy in combination with carfilzomib and dexamethasone (Isa-KD) for relapsed/refractory multiple myeloma (RRMM) treatment, as documented in the phase III IKEMA trial. However, real-world evidence on its...

Full description

Bibliographic Details

Published in:	Haematologica
Main Authors:	D. Derudas, D. Vincelli, R. Fontana, R. Della Pepa, S. Palmieri, F. Accardi, F. Rotondo, E. Morelli, E. Gigliotta, D. Roccotelli, L. Marano, M.l. Barone, G. Cetani, D. Esposito, A. Lazzaro, G. Delle Cave, B. Serio, D. Morini, M. Porrazzo, E. Urciuoli, C. Masucci, F. Fanelli, M. Rizzo, M. Arcamone, F. Trastulli, S. Rocco, A. Leone, R. Bianco, F. Salvatore, A. Idato, M. Sicari, P. Tosi, M.G. Rascato, M. Di Perna, A.P. Falcone, L. Morello, M. Carlisi, G. Svanera, G.R. Nunziata, M. Annunziata, F. Frigeri, C. Califano, A.M. Carella, G. Marcacci, F. Pane, A.M. Risitano, C. Botta
Format:	Article
Language:	English
Published:	Ferrata Storti Foundation 2025-09-01
Online Access:	https://haematologica.org/article/view/12370